These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 17284392

  • 1. [Therapeutic maintenance level of methotrexate in rheumatoid arthritis].
    Tahiri L, Allali F, Jroundi I, Abouqal R, Hajjaj-Hassouni N.
    Sante; 2006; 16(3):167-72. PubMed ID: 17284392
    [Abstract] [Full Text] [Related]

  • 2. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H, Ohno S, Ishigatsubo Y.
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [Abstract] [Full Text] [Related]

  • 4. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF.
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [Abstract] [Full Text] [Related]

  • 5. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.
    McKendry RJ, Dale P.
    J Rheumatol; 1993 Nov; 20(11):1850-6. PubMed ID: 8308769
    [Abstract] [Full Text] [Related]

  • 6. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study.
    Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA, Tacrolimus-Methotrexate Rheumatoid Arthritis Study Group.
    Arthritis Rheum; 2003 Oct; 48(10):2763-8. PubMed ID: 14558080
    [Abstract] [Full Text] [Related]

  • 7. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital.
    de Thurah A, Nørgaard M, Johansen M, Stengaard-Pedersen K.
    Scand J Rheumatol; 2010 Oct; 39(1):19-25. PubMed ID: 20132066
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
    Kent PD, Luthra HS, Michet C.
    J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
    [Abstract] [Full Text] [Related]

  • 9. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis.
    Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, Mimori T, Akizuki M, Ikeda Y.
    J Rheumatol; 1997 Dec; 24(12):2299-303. PubMed ID: 9415631
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE, Bochkova AG, Bunchuk NV.
    Ter Arkh; 2008 Dec; 80(5):25-30. PubMed ID: 18590110
    [Abstract] [Full Text] [Related]

  • 11. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.
    Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
    [Abstract] [Full Text] [Related]

  • 12. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, Freundlich B, Chang DJ, Etanercept Study 400 Investigators.
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [Abstract] [Full Text] [Related]

  • 13. [Undesirable effects of methothrexate during treatment of rheumatoid arthritis].
    Ndongo S, Ka MM, Pouye A, Ka EF, Diallo S, Diop TM.
    Dakar Med; 2007 Feb; 52(1):37-40. PubMed ID: 19102090
    [Abstract] [Full Text] [Related]

  • 14. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN.
    J Rheumatol; 2004 Jan; 31(1):179-82. PubMed ID: 14705239
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.
    Kapral T, Stamm T, Machold KP, Montag K, Smolen JS, Aletaha D.
    Arthritis Res Ther; 2006 Jan; 8(2):R46. PubMed ID: 16507172
    [Abstract] [Full Text] [Related]

  • 16. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
    Gilani ST, Khan DA, Khan FA, Ahmed M.
    J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
    [Abstract] [Full Text] [Related]

  • 17. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases.
    Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP.
    J Rheumatol; 1991 Sep; 18(9):1323-7. PubMed ID: 1757932
    [Abstract] [Full Text] [Related]

  • 18. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J.
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [Abstract] [Full Text] [Related]

  • 19. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
    Arthritis Res Ther; 2006 Jan; 8(5):R151. PubMed ID: 16984661
    [Abstract] [Full Text] [Related]

  • 20. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions.
    Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF.
    Rheumatology (Oxford); 2005 Jan; 44(1):61-6. PubMed ID: 15611303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.